4xg6 Citations

Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.

FEBS J 283 3613-3625 (2016)
Related entries: 4xg2, 4xg3, 4xg4, 4xg7, 4xg8, 4xg9, 5ghv

Cited: 8 times
EuropePMC logo PMID: 27504936

Abstract

Spleen tyrosine kinase (SYK) is a cytosolic nonreceptor protein tyrosine kinase that mediates key signal transduction pathways following the activation of immune cell receptors. SYK regulates cellular events induced by the B-cell receptor and Fc receptors with high intrinsic activity. Furthermore, SYK has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Here, we report the crystal structures of SYK in complex with seven newly developed inhibitors (G206, G207, O178, O194, O259, O272, and O282) to provide structural insights into which substituents of the inhibitors and binding regions of SYK are essential for lead compound optimization. Our kinase inhibitors exhibited high inhibitory activities against SYK, with half-maximal inhibitory concentrations (IC50 ) of approximately 0.7-33 nm, but they showed dissimilar inhibitory activities against KDR, RET, JAK2, JAK3, and FLT3. Among the seven SYK inhibitors, O272 and O282 exhibited highly specific inhibitions against SYK, whereas O194 exhibited strong inhibition of both SYK and FLT3. Three inhibitors (G206, G207, and O178) more efficiently inhibited FLT3 while still substantially inhibiting SYK activity. The binding mode analysis suggested that a highly selective SYK inhibitor can be developed by optimizing the functional groups that facilitate direct interactions with Asn499.

Articles - 4xg6 mentioned but not cited (2)

  1. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs. Lee SJ, Choi JS, Han BG, Kim HS, Song HJ, Lee J, Nam S, Goh SH, Kim JH, Koh JS, Lee BI. FEBS J 283 3613-3625 (2016)
  2. A computational multi-targeting approach for drug repositioning for psoriasis treatment. Ibezim A, Onah E, Dim EN, Ntie-Kang F. BMC Complement Med Ther 21 193 (2021)


Articles citing this publication (6)

  1. Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells. Gao D, Wang L, Zhang H, Yan X, Yang J, Zhou R, Chang X, Sun Y, Tian S, Yao Z, Zhang K, Liu Z, Ma Z. FEBS J 285 4229-4245 (2018)
  2. Cancer Transcriptome Dataset Analysis: Comparing Methods of Pathway and Gene Regulatory Network-Based Cluster Identification. Nam S. OMICS 21 217-224 (2017)
  3. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors. Kumar V, Parate S, Danishuddin, Zeb A, Singh P, Lee G, Jung TS, Lee KW, Ha MW. Front Cell Infect Microbiol 12 909111 (2022)
  4. Historical Article 50 years of The FEBS Journal: looking back as well as ahead. Chenette EJ, Martin SJ. FEBS J 284 4162-4171 (2017)
  5. Characterizing the structure-activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase. Tung MC, Tsai KC, Fung KM, Don MJ, Tseng TS. RSC Adv 11 2453-2461 (2021)
  6. Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors. Lee SJ, Choi JS, Bong SM, Hwang HJ, Lee J, Song HJ, Lee J, Kim JH, Koh JS, Lee BI. Mol Cells 41 545-552 (2018)